2019 | 2018 | 2017 | 2016 | 2015

La Jolla Pharmaceutical Company Announces FDA Approval of Giapreza™ (angiotensin II)

12/21/17

Giapreza increases blood pressure in adults with septic or other distributive shock La Jolla to host conference call and webcast at 8:30 a.m. EST on December 22, 2017 SAN DIEGO, Dec. 21, 2017 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (N

Read More

La Jolla Pharmaceutical Company Announces Initiation of Multicenter, Randomized, Phase 2 Clinical Study of LJPC‑401 in Patients with Hereditary Hemochromatosis

12/18/17

SAN DIEGO, Dec. 18, 2017 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) (the Company or La Jolla) today announced the initiation of LJ401-HH01, a Phase 2 clinical study of LJPC‑401 (synthetic human hepcidin) in patients with here

Read More

La Jolla Pharmaceutical Company Announces Initiation of Pivotal Clinical Study of LJPC‑401 in Patients with Beta Thalassemia

12/04/17

SAN DIEGO, Dec. 04, 2017 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) (the Company or La Jolla) today announced the initiation of a pivotal clinical study of LJPC‑401 (synthetic human hepcidin) in patients with transfusion-depe

Read More

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress

10/26/17

SAN DIEGO--(BUSINESS WIRE)--Oct. 26, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patien

Read More

La Jolla Pharmaceutical Company Announces Intent to Submit Marketing Authorization Application for LJPC-501 in the Third Quarter of 2018

09/25/17

-- Decision follows successful Scientific Advice meeting with European Medicines Agency -- SAN DIEGO--(BUSINESS WIRE)--Sep. 25, 2017-- La Jolla Pharmaceutical Company (NASDAQ:LJPC) (the Company or La Jolla) toda

Read More

Prespecified Analysis of ATHOS-3 Indicates Survival Benefit in LJPC-501-Treated Patients with Relatively Low Angiotensin II State

09/20/17

Analysis to Be Presented in Oral Session at the 30th Annual Congress of The European Society of Intensive Care Medicine SAN DIEGO--(BUSINESS WIRE)--Sep. 20, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Co

Read More

La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance of New Drug Application for LJPC-501

08/28/17

– Priority Review Granted – SAN DIEGO--(BUSINESS WIRE)--Aug. 28, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla) today announced that the U.S. Food and Drug Administration (FDA) h

Read More

La Jolla Pharmaceutical Company Announces Launch of Expanded Access Program for LJPC-501

08/08/17

SAN DIEGO--(BUSINESS WIRE)--Aug. 8, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), today announced that the Company has initiated an expanded access program (EAP) in the United States to p

Read More

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2017 and Recent Corporate Progress

07/27/17

SAN DIEGO--(BUSINESS WIRE)--Jul. 27, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patien

Read More

Results of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Journal of Medicine

05/21/17

SAN DIEGO--(BUSINESS WIRE)--May 21, 2017-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (La Jolla) today announced that results of the ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock) Phase 3 study of LJPC

Read More

La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate Progress

04/27/17

SAN DIEGO--(BUSINESS WIRE)--Apr. 27, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patien

Read More

La Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common Stock

03/23/17

SAN DIEGO--(BUSINESS WIRE)--Mar. 23, 2017-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (“La Jolla” or the “Company”), a leader in the development of innovative therapies intended to significantly improve outcomes in patients

Read More

La Jolla Pharmaceutical Company Announces Proposed Underwritten Public Offering of Common Stock

03/20/17

SAN DIEGO--(BUSINESS WIRE)--Mar. 20, 2017-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (“La Jolla” or the “Company), a leader in the development of innovative therapies intended to significantly improve outcomes in patients s

Read More

La Jolla Pharmaceutical Company Announces Positive Top-Line Results from ATHOS-3 Phase 3 Study of LJPC-501

02/27/17

-- Primary efficacy endpoint analysis highly statistically significant (p<0.00001) -- Trend toward longer survival observed -- New Drug Application planned for second half of 2017 -- Company to h

Read More

La Jolla Pharmaceutical Company Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Progress

02/23/17

SAN DIEGO--(BUSINESS WIRE)--Feb. 23, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patien

Read More



Print Page Print PageE-mail Page E-mail PageRSS Feeds RSS FeedsE-mail Alerts E-mail AlertsIR Contacts IR Contacts